Feasibility and attractiveness of indication value-based pricing in key EU countries

Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use...

Descripción completa

Detalles Bibliográficos
Autores principales: Flume, Mathias, Bardou, Marc, Capri, Stefano, Sola-Morales, Oriol, Cunningham, David, Levin, Lars-Ake, Touchot, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864834/
https://www.ncbi.nlm.nih.gov/pubmed/27226845
http://dx.doi.org/10.3402/jmahp.v4.30970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864834/
https://www.ncbi.nlm.nih.gov/pubmed/27226845
http://dx.doi.org/10.3402/jmahp.v4.30970

Ejemplares similares